HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $17.37 million. The enterprise value is $29.30 million.
Important Dates
The next estimated earnings date is Monday, March 31, 2025, after market close.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 44.54 million shares outstanding. The number of shares has increased by 3.68% in one year.
| Current Share Class | 44.54M |
| Shares Outstanding | 44.54M |
| Shares Change (YoY) | +3.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 40.57% |
| Owned by Institutions (%) | 6.92% |
| Float | 26.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.15 |
| Forward PS | 2.43 |
| PB Ratio | -1.74 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -93.78 |
Financial Efficiency
Return on equity (ROE) is -537.24% and return on invested capital (ROIC) is -134.15%.
| Return on Equity (ROE) | -537.24% |
| Return on Assets (ROA) | -71.95% |
| Return on Invested Capital (ROIC) | -134.15% |
| Return on Capital Employed (ROCE) | 1,020.52% |
| Revenue Per Employee | $77,689 |
| Profits Per Employee | -$829,579 |
| Employee Count | 45 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.18% in the last 52 weeks. The beta is 0.81, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -65.18% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.60 |
| Relative Strength Index (RSI) | 48.72 |
| Average Volume (20 Days) | 18,290,227 |
Short Selling Information
The latest short interest is 83,110, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 83,110 |
| Short Previous Month | 55,119 |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $3.50 million and -$37.33 million in losses. Loss per share was -$1.00.
| Revenue | 3.50M |
| Gross Profit | -4.12M |
| Operating Income | -35.79M |
| Pretax Income | -27.39M |
| Net Income | -37.33M |
| EBITDA | -35.34M |
| EBIT | -35.79M |
| Loss Per Share | -$1.00 |
Full Income StatementBalance Sheet
The company has $998,221 in cash and $12.93 million in debt, giving a net cash position of -$11.93 million or -$0.27 per share.
| Cash & Cash Equivalents | 998,221 |
| Total Debt | 12.93M |
| Net Cash | -11.93M |
| Net Cash Per Share | -$0.27 |
| Equity (Book Value) | -9.97M |
| Book Value Per Share | -0.26 |
| Working Capital | -27.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.29 million and capital expenditures -$3.86 million, giving a free cash flow of -$19.15 million.
| Operating Cash Flow | -15.29M |
| Capital Expenditures | -3.86M |
| Free Cash Flow | -19.15M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
| Gross Margin | -117.76% |
| Operating Margin | -1,023.69% |
| Pretax Margin | -1,067.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |